The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress

Journal of Neurochemistry

Volumn 125, Issue 6, 2013, Pages 932-943

  Luk, Kelvin C ^a   Rymar, Vladimir V ^a   Van Den Munckhof, Pepijn ^b   Nicolau, Stefan ^a   Steriade, Claude ^a   Bifsha, Panojot ^b   Drouin, Jacques ^b   Sadikot, Abbas F ^a  

^a MCGILL UNIVERSITY   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

aphakia mouse; calbindin D28k; development; MPTP; Parkinson's disease; substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CALBINDIN; TRANSCRIPTION FACTOR PITX3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MAPPING; CELL COUNT; CELL LOSS; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE PREDISPOSITION; DISEASE RESISTANCE; DOPAMINERGIC NERVE CELL; INTRACELLULAR SIGNALING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AGING; ANIMALS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CELL COUNT; CELL SURVIVAL; DOPAMINERGIC NEURONS; GENE DOSAGE; HOMEODOMAIN PROTEINS; MALE; MESENCEPHALON; MICE; MICE, MUTANT STRAINS; NERVE DEGENERATION; PARKINSON DISEASE; SUBSTANTIA NIGRA; TRANSCRIPTION FACTORS;

ANIMALIA; MUS;

EID: 84878758640     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12160     Document Type: Article

References (69)

1. Airaksinen M. S., Thoenen H., and, Meyer M., (1997) Vulnerability of midbrain dopaminergic neurons in calbindin-D28k-deficient mice: lack of evidence for a neuroprotective role of endogenous calbindin in MPTP-treated and weaver mice. Eur. J. Neurosci. 9, 120-127.
2. Alberi L., Sgado P., and, Simon H. H,. (2004) Engrailed genes are cell-autonomously required to prevent apoptosis in mesencephalic dopaminergic neurons. Development 131, 3229-3236.
3. Andersson E., Tryggvason U., Deng Q., Friling S., Alekseenko Z., Robert B., Perlmann T., and, Ericson J., (2006) Identification of intrinsic determinants of midbrain dopamine neurons. Cell 124, 393-405.
4. Ardayfio P. A., Leung A., Park J., Hwang D. Y., Moran-Gates T., Choi Y. K., Carlezon W. A. Jr, Tarazi F. I., and, Kim K. S., (2010) Pitx3-deficient aphakia mice display unique behavioral responses to psychostimulant and antipsychotic drugs. Neuroscience 166, 391-396.
5. Asbreuk C. H., Vogelaar C. F., Hellemons A., Smidt M. P., and, Burbach J. P., (2002) CNS expression pattern of Lmx1b and coexpression with ptx genes suggest functional cooperativity in the development of forebrain motor control systems. Mol. Cell. Neurosci. 21, 410-420.
6. Beeler J. A., Cao Z. F., Kheirbek M. A., Ding Y., Koranda J., Murakami M., Kang U. J., and, Zhuang X., (2010) Dopamine-dependent motor learning: insight into levodopa's long-duration response. Ann. Neurol. 67, 639-647.
7. Bergman O., Hakansson A., Westberg L., Carmine Belin A., Sydow O., Olson L., Holmberg B., Eriksson E., and, Nissbrandt H., (2010) PITX3 polymorphism is associated with early onset Parkinson's disease. Neurobiol. Aging 31, 114-117.
8. Bjorklund A., and, Lindvall O., (1975) Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals. Brain Res. 83, 531-537.
9. Braak H., Del Tredici K., Rub U., De Vos R. A. I., Steur E. N. H. J., and, Braak E., (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211.
10. Brown M. T., Henny P., Bolam J. P., and, Magill P. J., (2009) Activity of neurochemically heterogeneous dopaminergic neurons in the substantia nigra during spontaneous and driven changes in brain state. J. Neurosci. 29, 2915-2925.
11. Damier P., Hirsch E. C., Agid Y., and, Graybiel A. M,. (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain, 122 (Pt 8), 1437-1448.
12. Dauer W., and, Przedborski S., (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909.
13. Dawson T. M., and, Dawson V. L,. (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822.
14. Fallon J. H., and, Moore R. Y., (1978) Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J. Comp. Neurol. 180, 545-580.
15. Fearnley J. M., and, Lees A. J., (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 2283-2301.
16. Friling S., Andersson E., Thompson L. H., et al,. (2009) Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc. Natl Acad. Sci. USA 106, 7613-7618.
17. Fu Y., Yuan Y., Halliday G., Rusznak Z., Watson C., and, Paxinos G., (2012) A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Struct. Funct. 217, 591-612.
18. Gaspar P., Ben Jelloun N., and, Febvret A., (1994) Sparing of the dopaminergic neurons containing calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mice. Neuroscience 61, 293-305.
19. Gerfen C. R., Baimbridge K. G., and, Thibault J., (1987) The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems. J. Neurosci. 7, 3935-3944.
20. German D. C., Manaye K. F., Sonsalla P. K., and, Brooks B. A., (1992) Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann. N. Y. Acad. Sci. 648, 42-62.
21. Haber S. N., Ryoo H., Cox C., and, Lu W., (1995) Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J. Comp. Neurol. 362, 400-410.
22. Halliday G. M., and, McCann H., (2010) The progression of pathology in Parkinson's disease. Ann. N. Y. Acad. Sci. 1184, 188-195.
23. Haubenberger D., Reinthaler E., Mueller J. C., et al,. (2011) Association of transcription factor polymorphisms PITX3 and EN1 with Parkinson's disease. Neurobiol. Aging 32, 302-307.
24. Hornykiewicz O., (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18, 925-964.
25. Hwang D. Y., Ardayfio P., Kang U. J., Semina E. V., and, Kim K. S., (2003) Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res. 114, 123-131.
26. Hwang D. Y., Fleming S. M., Ardayfio P., Moran-Gates T., Kim H., Tarazi F. I., Chesselet M. F., and, Kim K. S., (2005) 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J. Neurosci. 25, 2132-2137.
27. Jacobs F. M., Smits S. M., Noorlander C. W., von Oerthel L., van der Linden A. J., Burbach J. P., and, Smidt M. P,. (2007) Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency. Development 134, 2673-2684.
28. Jacobs F. M., van Erp S., van der Linden A. J., von Oerthel L., Burbach J. P., Smidt, and, M. P,. (2009) Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression. Development, 136, 531-540.
29. Jacobs F. M., Veenvliet J. V., Almirza W. H,. et al. (2011) Retinoic acid-dependent and -independent gene-regulatory pathways of Pitx3 in meso-diencephalic dopaminergic neurons. Development 138, 5213-5222.
30. Jellinger K. A., (2012) Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov. Disord. 27, 8-30.
31. Kas M. J., van der Linden A. J., Oppelaar H., von Oerthel L., Ramakers G. M., and, Smidt M. P., (2008) Phenotypic segregation of aphakia and Pitx3-null mutants reveals that Pitx3 deficiency increases consolidation of specific movement components. Behav. Brain Res. 186, 208-214.
32. Kim J., Inoue K., Ishii J., Vanti W. B., Voronov S. V., Murchison E., Hannon G., and, Abeliovich A,. (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317, 1220-1224.
33. Kish S. J., Shannak K., and, Hornykiewicz O., (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318, 876-880.
34. Korotkova T. M., Ponomarenko A. A., Brown R. E., and, Haas H. L., (2004) Functional diversity of ventral midbrain dopamine and GABAergic neurons. Mol. Neurobiol. 29, 243-259.
35. Landau A. M., Luk K. C., Jones M. L., et al,. (2005) Defective Fas expression exacerbates neurotoxicity in a model of Parkinson's disease. J. Exp. Med. 202, 575-581.
36. Lavoie B., and, Parent A., (1991) Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys. NeuroReport 2, 601-604.
37. Lebel M., Gauthier Y., Moreau A., and, Drouin J., (2001) Pitx3 activates mouse tyrosine hydroxylase promoter via a high-affinity binding site. J. Neurochem. 77, 558-567.
38. Liang C. L., Sinton C. M., Sonsalla P. K., and, German D. C,. (1996) Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration 5, 313-318.
39. Liss B., Neu A., and, Roeper J., (1999) The weaver mouse gain-of-function phenotype of dopaminergic midbrain neurons is determined by coactivation of wvGirk2 and K-ATP channels. J. Neurosci. 19, 8839-8848.
40. Liu J., Sun Q. Y., Tang B. S., et al,. (2011) PITX3 gene polymorphism is associated with Parkinson's disease in Chinese population. Brain Res. 1392, 116-120.
41. Matzuk M. M., and, Saper C. B., (1985) Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann. Neurol. 18, 552-555.
42. Maxwell S. L., Ho H. Y., Kuehner E., Zhao S., and, Li M., (2005) Pitx3 regulates tyrosine hydroxylase expression in the substantia nigra and identifies a subgroup of mesencephalic dopaminergic progenitor neurons during mouse development. Dev. Biol. 282, 467-479.
43. McRitchie D. A., Hardman C. D., and, Halliday G. M., (1996) Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J. Comp. Neurol. 364, 121-150.
44. Mizuta I., Tsunoda T., Satake W., et al,. (2008) Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease. Hum. Genet. 124, 89-94.
45. Mosharov E. V., Larsen K. E., Kanter E., et al,. (2009) Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62, 218-229.
46. van den Munckhof P., Luk K. C., Ste-Marie L., Montgomery J., Blanchet P. J., Sadikot A. F., and, Drouin J,. (2003) Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 130, 2535-2542.
47. van den Munckhof P., Gilbert F., Chamberland M., Lévesque D., and, Drouin J., (2006) Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of Parkinson's disease. J. Neurochem. 96, 160-170.
48. Nelson E. L., Liang C. L., Sinton C. M., and, German D. C., (1996) Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J. Comp. Neurol. 369, 361-371.
49. Nemoto C., Hida T., and, Arai R., (1999) Calretinin and calbindin-D28k in dopaminergic neurons of the rat midbrain: a triple-labeling immunohistochemical study. Brain Res. 846, 129-136.
50. Nunes I., Tovmasian L. T., Silva R. M., Burke R. E., and, Goff S. P., (2003) Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc. Natl Acad. Sci. USA 100, 4245-4250.
51. Ono Y., Nakatani T., Sakamoto Y,. et al. (2007) Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells. Development 134, 3213-3225.
52. Paxinos G., and, Franklin K. B. J., (2004) The Mouse Brain in Stereotaxic Coordinates. Academic Press.
53. Peng C., Aron L., Klein R., Li M., Wurst W., Prakash N., and, Le W., (2011) Pitx3 is a critical mediator of GDNF-induced BDNF expression in nigrostriatal dopaminergic neurons. J. Neurosci. 31, 12802-12815.
54. Rieger D. K., Reichenberger E., McLean W., Sidow A., and, Olsen B. R., (2001) A double-deletion mutation in the Pitx3 gene causes arrested lens development in aphakia mice. Genomics 72, 61-72.
55. Sanghera M. K., Manaye K., McMahon A., Sonsalla P. K., and, German D. C., (1997) Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP. NeuroReport 8, 3327-3331.
56. Semina E. V., Reiter R. S., and, Murray J. C., (1997) Isolation of a new homeobox gene belonging to the Pitx/Rieg family: expression during lens development and mapping to the aphakia region on mouse chromosome 19. Hum. Mol. Genet. 6, 2109-2116.
57. Sgado P., Alberi L., Gherbassi D., Galasso S. L., Ramakers G. M., Alavian K. N., Smidt M. P., Dyck R. H., and, Simon H. H., (2006) Slow progressive degeneration of nigral dopaminergic neurons in postnatal Engrailed mutant mice. Proc. Natl Acad. Sci. USA 103, 15242-15247.
58. Smidt M. P., van Schaick H. S., Lanctot C., Tremblay J. J., Cox J. J., van der Kleij A. A., Wolterink G., Drouin J., and, Burbach J. P., (1997) A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons. Proc. Natl Acad. Sci. USA 94, 13305-13310.
59. Smidt M. P., Asbreuk C. H., Cox J. J., Chen H., Johnson R. L., and, Burbach J. P., (2000) A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. Nat. Neurosci. 3, 337-341.
60. Smidt M. P., Smits S. M., Bouwmeester H., Hamers F. P., van der Linden A. J., Hellemons A. J., Graw J., and, Burbach J. P,. (2004) Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3. Development 131, 1145-1155.
61. Sourkes T. L., and, Poirier L., (1965) Influence of the substantia nigra on the concentration of 5-hydroxytryptamine and dopamine of the striatum. Nature 207, 202-203.
62. Surmeier D. J., Guzman J. N., Sanchez-Padilla J., and, Schumacker P. T., (2011) The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience 198, 221-231.
63. Tsuboi K., Kimber T. A., and, Shults C. W., (2000) Calretinin-containing axons and neurons are resistant to an intrastriatal 6-hydroxydopamine lesion. Brain Res. 866, 55-64.
64. Varnum D. S., and, Stevens L. C., (1968) Aphakia, a new mutation in the mouse. J. Hered. 59, 147-150.
65. Wallen A., and, Perlmann T., (2003) Transcriptional control of dopamine neuron development. Ann. N. Y. Acad. Sci. 991, 48-60.
66. Yamada T., McGeer P. L., Baimbridge K. G., and, McGeer E. G., (1990) Relative Sparing in Parkinsons-Disease of Substantia-Nigra Dopamine Neurons Containing Calbindin-D28K. Brain Res. 526, 303-307.
67. Yu L. H., Lin Z. F., Liu Y., Hu F. Y., He X. H., Liu Z. L., and, Xu Y. M., (2010) The transcription factor Pitx3 is a risk modifier for Parkinson's disease in a Chinese Han population. Eur J Neurol.
68. Zetterstrom R. H., Solomin L., Jansson L., Hoffer B. J., Olson L., and, Perlmann T,. (1997) Dopamine neuron agenesis in Nurr1-deficient mice. Science 276, 248-250.
69. Zhao S., Maxwell S., Jimenez-Beristain A., et al,. (2004) Generation of embryonic stem cells and transgenic mice expressing green fluorescence protein in midbrain dopaminergic neurons. Eur. J. Neurosci. 19, 1133-1140.